Marcelina Niemiec-Urbanczyk

Dr. Marcelina Niemiec-Urbanczyk

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Contemporary Oncology
Verified
Journal Article
Open access
PDF file
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
GSGrażyna Stryjewska-Makuch
Grażyna Stryjewska-Makuch
MJMałgorzata A. Janik
Małgorzata A. Janik
BKBogdan Kolebacz
Bogdan Kolebacz
GLGrażyna Lisowska
Grażyna Lisowska
WŚWojciech Ścierski
Wojciech Ścierski
Aim of the study : Lymphomas are a heterogeneous group of tumours of lymphoid tissue in which there is an abnormal proliferation of cells of the lymphatic system. The literature notes a gradual increase in the incidence of this type of cancer in the whole population. The aim of the study was to...

25 February 2021 in Polish Archives of Internal Medicine
Verified
Journal Article
Closed access
GSGrażyna Stryjewska-Makuch
Grażyna Stryjewska-Makuch
JGJoanna Glück
Joanna Glück
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
MHMaria Humeniuk-Arasiewicz
Maria Humeniuk-Arasiewicz
BKBogdan Kolebacz
Bogdan Kolebacz
ALAnetta Lasek-Bal
Anetta Lasek-Bal
DOI: 10.20452/pamw.15848, Published online: February 25, 2021, Authors: Grażyna Stryjewska-Makuch, Joanna Glück, Marcelina Niemiec-Urbańczyk, Maria Humeniuk-Arasiewicz, Bogdan Kolebacz, Anetta Lasek-Bal

25 November 2025 in Otolaryngologia Polska
Verified
Journal Article
Closed access
GSGrażyna Stryjewska-Makuch
Grażyna Stryjewska-Makuch
MHMaria Humeniuk-Arasiewicz
Maria Humeniuk-Arasiewicz
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
MMMarta Michalak-Kolarz
Marta Michalak-Kolarz
JGJoanna Gluck
Joanna Gluck
Introduction: Primary chronic rhinosinusitis with nasal polyps (CRSwNP) is a severe, often uncontrolled disease whose pathomechanism involves type 2 inflammation (T2). Biologic drugs targeting interleukin 4 and 13 (dupilumab) receptors and blocking interleukin 5 (mepolizumab) have been approved for the treatment of the T2 endotype.Aim: Presentation of the authors’ suggestions that guided the choice of an appropriate biologic agent when initiating qualification for the treatment of patients with CRSwNP, based on the authors’ experience and data from the literature related to biologic therapy.Materials and methods: Patients with CRSwNP were qualified for biological treatment in accordance with the EPOS (European Position Paper on Rhinosinusitis) guidelines and the criteria of the B.156 drug program. The choice of an appropriate biologic was based on medical history data, such as the level of asthma control, presence of allergies, and the occurrence of N-ERD (nonsteroidal anti-inflammatory drug–exacerbated respiratory disease), as well as biomarker results: total IgE concentration and absolute blood eosinophil count.Results: The study included 43 patients (23 treated with mepolizumab, 20 treated with dupilumab). Groups of patients were comparable in terms of age, sex, number of sinonasal surgeries, prevalence of asthma, NSAIDs (non-steroidal anti-inflammatory drugs) sensitivity, atopy and initial SNOT-22 (Sinonasal Outcome Test-22), VAS (Visual Analog Scale), NPS (Nasal Polyp Score), and L-K score (Lund-Kennedy score). Eosinophilia total range was 250–1000 cells/microL. Baseline peripheral blood eosinophil count was significantly higher in the mepolizumab-treated group. In the dupilumab-treated group, increases in eosinophil counts up to 3500 cells/μl were observed during therapy; however, no patient developed clinical features of hypereosinophilic syndrome.Conclusions: When selecting a biologic drug for the treatment of CRSwNP, it is recommended to consider not only the values of available biomarkers, but also the degree of asthma control, the cumulative dose of oral corticosteroids (OCSs), the patient’s age, and treatment convenience for the patient.

11 December 2013 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Łukasz J. KrzychŁukasz J. Krzych
Łukasz J. Krzych
MLMałgorzata Lach
Małgorzata Lach
SMSara Mustafa
Sara Mustafa
MJMichał Joniec
Michał Joniec
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
ABAndrzej Bochenek
Andrzej Bochenek
Background: We sought to evaluate patients’ adherence to optimal pharmacotherapy as recommended by the European Society of Cardiology, together with the assessment of potential clinical determinants of medical non-compliance in a large cohort of patients after endoscopic atraumatic coronary artery bypassing (EACAB). Methods: This cross sectional study was conducted in a group of 706 individuals who underwent EACAB between April 1998 and December 2010. Data covering current pharmacological treatment with antiplatelet agents, beta-blockers (BB) (or heart rate lowering calcium channel blockers [CCB] in case of intolerance and/or poor efficacy of beta-blockade), angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor blockers [ARB]) and statins was acquired. Mean duration of observation after the surgery was 2132 ± 1313 days. Results: Complete follow-up data has been obtained from 415 living patients (341 males). Amongst them, 353 (85%) received antiplatelet agents, while BB or CCB were routinely ingested by 349 (84%) patients. Statins were used by 310 (74.7%) individuals and 274 (66%) subjects took ACE inhibitors or ARB. Baseline demographic and clinical features, including major co-morbidities had no impact on patients’ compliance with all investigated medications. There was no clear association between adherence to treatment and risk of rehospitalization or occurrence of major cerebral and cardiovascular events. Conclusions: EACAB patients’ compliance with pharmacotherapy guidelines is insufficient and is unrelated to demographic and clinical features of the subjects. Multidisciplinary approach involving health education, enhancement in prescription drug affordability and a better rapport between doctors and patients should be incorporated into clinical practice to overcome therapeutic disobedience. Background: We sought to evaluate patients’ adherence to optimal pharmacotherapy as recommended by the European Society of Cardiology, together with the assessment of potential clinical determinants of medical non-compliance in a large cohort of patients after endoscopic atraumatic coronary artery bypassing (EACAB). Methods: This cross sectional study was conducted in a group of 706 individuals who underwent EACAB between April 1998 and December 2010. Data covering current pharmacological treatment with antiplatelet agents, beta-blockers (BB) (or heart rate lowering calcium channel blockers [CCB] in case of intolerance and/or poor efficacy of beta-blockade), angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor blockers [ARB]) and statins was acquired. Mean duration of observation after the surgery was 2132 ± 1313 days. Results: Complete follow-up data has been obtained from 415 living patients (341 males). Amongst them, 353 (85%) received antiplatelet agents, while BB or CCB were routinely ingested by 349 (84%) patients. Statins were used by 310 (74.7%) individuals and 274 (66%) subjects took ACE inhibitors or ARB. Baseline demographic and clinical features, including major co-morbidities had no impact on patients’ compliance with all investigated medications. There was no clear association between adherence to treatment and risk of rehospitalization or occurrence of major cerebral and cardiovascular events. Conclusions: EACAB patients’ compliance with pharmacotherapy guidelines is insufficient and is unrelated to demographic and clinical features of the subjects. Multidisciplinary approach involving health education, enhancement in prescription drug affordability and a better rapport between doctors and patients should be incorporated into clinical practice to overcome therapeutic disobedience.

31 December 2019 in Nowotwory. Journal of Oncology
Verified
Journal Article
Open access
PDF file
GSGrażyna Stryjewska-Makuch
Grażyna Stryjewska-Makuch
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
BKBogdan Kolebacz
Bogdan Kolebacz
Olfactory neuroblastoma (ONB), also called esthesioneuroblastoma, is a rare tumour that occurs in the nasal cavity and paranasal sinuses. The symptoms that patients report are similar to chronic rhinosinusitis (CRS). The authors present the case of a patient referred to hospital due to nasal obstruction on the left side. The performed endoscopic surgery revealed within the left middle nasal concha a tumour penetrating into the anterior ethmoid and frontal recess. ONB was diagnosed in the histopathological examination. The patient was qualified for complementary radiotherapy. The patient has been under medical supervision for 24 months. There have been no signs of recurrence. It was decided to present the above case due to the lack of deviations in the ENT endoscopy and minor ailments reported by the patient, which in combination with advanced age could lead to discontinuation of surgical treatment. Olfactory neuroblastoma (ONB), also called esthesioneuroblastoma, is a rare tumour that occurs in the nasal cavity and paranasal sinuses. The symptoms that patients report are similar to chronic rhinosinusitis (CRS). The authors present the case of a patient referred to hospital due to nasal obstruction on the left side. The performed endoscopic surgery revealed within the left middle nasal concha a tumour penetrating into the anterior ethmoid and frontal recess. ONB was diagnosed in the histopathological examination. The patient was qualified for complementary radiotherapy. The patient has been under medical supervision for 24 months. There have been no signs of recurrence. It was decided to present the above case due to the lack of deviations in the ENT endoscopy and minor ailments reported by the patient, which in combination with advanced age could lead to discontinuation of surgical treatment.

10 July 2025 in Allergy
Verified
Journal Article
Open access
GSGrażyna Stryjewska‐Makuch
Grażyna Stryjewska‐Makuch
MHMaria Humeniuk‐Arasiewicz
Maria Humeniuk‐Arasiewicz
MOMagdalena Onyszczuk
Magdalena Onyszczuk
MKMagdalena Kokoszka
Magdalena Kokoszka
MNMarcelina Niemiec-Urbanczyk
Marcelina Niemiec-Urbanczyk
JGJoanna Gluck
Joanna Gluck